NR1H4 and metabolic dysfunction-associated steatotic liver disease: Currently, no approved treatments exist for MASLD, although many drugs have shown promise in clinical trials, including farnesoid X receptor (FXR) agonist (obeticholic acid), peroxisome proliferator-activated receptor (PPAR) agonists (elafibrinor), and C-C chemokine receptor (CCR) antagonist (cencriviroc) [3].